EICHORCondition: Advanced Solid Tumors · Sponsor: EMD Serono Research & Development Institute, Inc.
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
This description comes directly from the study's public registry record.
US Medical Information · 888-275-7376 · eMediUSA@emdserono.com
Communication Center · +49 6151 72 5200 · service@emdgroup.com
Always discuss trial participation with your own doctor first.
| Yale University - Yale University School of Medicine | New Haven, Connecticut, United States | Not Yet Recruiting |
| Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center | Huntersville, North Carolina, United States | Recruiting |
| NEXT Houston | Galveston, Texas, United States | Recruiting |
| NEXT Oncology - PARENT | San Antonio, Texas, United States | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Canada | Recruiting |
| BC Cancer - Vancouver - BC Cancer Agency | Vancouver, Canada | Not Yet Recruiting |
| National Cancer Center Hospital | Tokyo, Japan | Recruiting |
| Hospital Universitari Vall d'Hebron - VHIO - Oncology - Phase I Unit | Barcelona, Spain | Not Yet Recruiting |
| NEXT Madrid - Hospital Universitario Quironsalud Madrid | Madrid, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07360314